MedPath

Influence of somatic mutational status of DNA repair genes on the clinical course in men with High risk-prostate cancer - a prospective biomarker study

Conditions
High grade prostate carcinoma
C61
Malignant neoplasm of prostate
Registration Number
DRKS00015159
Lead Sponsor
niversitätsklinikum Heidelberg Nationales Centrum für Tumorerkrankungen (NCT) Medizinische Onkologie und Urologische Klinik
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Male
Target Recruitment
197
Inclusion Criteria

• Histological subtype: adenocarcinoma of the prostate without neuroendocrine differentiation
• age at disease onset =50 years and/or
• M1 (primary metastasized; every Gleason score, every T, every N, every M) and/or
• Gleason Score 9 or 10 (every T, every M) and/or
• Gleason Score 8 in combination with =pT3 or N1 or PSA =20 ng/ml and/or
• early tumor recurrence or persistence after local therapy (Prostatectomy or Radiotherapy of the prostate) within =12 months and with high PSA doubling time of =3 months and/or
• early development of castrations resistance of the prostate cancer under first line treatment with ADT alone or combination of ADT with Docetaxel or Abiraterone
• no contraindication for approved treatments
• ECOG: 0-1
• availability of tumor tissue in good quality for DNA sequencing
• Complete clinical documentation (PSA at diagnosis, histology, Gleason Score, TNM-Score, course of treatment, course of PSA, radiological reports of all scans since the time of diagnosis

Exclusion Criteria

• pre-existing psychiatric disorder
• other active malignant diseases
• non legally competent or incapacitated patients
• patients, who refuse to undergo systemic treatments

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
progression of disease
Secondary Outcome Measures
NameTimeMethod
overall survival
© Copyright 2025. All Rights Reserved by MedPath